The recent JAMA Pediatrics study has revealed a crucial finding about the effectiveness of infant RSV immunisation. While it's been widely believed that immunisation provides long-term protection against Respiratory Syncytial Virus (RSV), the study suggests otherwise. The research, which followed infants over a year, found that the protection offered by the nirsevimab vaccine does not extend into the second year of life